Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Thrombocytopenic Subjects with Advanced MDS or sAML/MDS
2009-015512-17Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by GSK. Primary endpoints: Safety and tolerability and Effect on platelet counts. Started Oct 2009; status: completed.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-015512-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015512-17.